Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 5082
Sealed predictions
- GTF2IRD1 in dopamine neurons, braak-0.59 (p 0.098) → -0.17 (p 0.663)receipt 5089
Swarm cases
receipt 5089: GTF2IRD1 in dopamine neurons, braak
- power
- full sample -0.45 (p 0.062, n 18), 95% CI -0.76 to +0.02. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.48 (p 0.044, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.026, n 18). not the mix.
- skeptic
- leave-one-out range -0.55 to -0.38, sign flips 0; without severely affected donors -0.45 (p 0.062, n 18). robust.
- cell type
- strongest in OPCs: -0.75 (p 3.7e-4, n 18) vs -0.45 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GTF2IRD1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GTF2IRD1 · OPCs · braak: substantia nigra, an independent cohort: not measured
Receipts
loading the receipts